Effects of transferred NK4 gene on proliferation, migration, invasion and apoptosis of human prostate cancer DU145 cells.
We investigated the ability of NK4, an antagonist of human hepatocyte growth factor (HGF), to inhibit the influence of HGF on proliferation, migration, invasion and apoptosis of human prostate cancer cells. Expression vector pBudCE4.1-EGFP-NK4 containing NK4 cDNA was used to transfect human prostate cancer DU145 cells, and the effects of the autocrine NK4 on tumor cell proliferation, migration, invasion and apoptosis were assessed in vitro. In vivo, we subcutaneously implanted DU145 cells, mock-transfected clone (DU145/empty vector) cells and NK4-transfected clone (DU145/NK4) cells into nude mice, and then evaluated tumor growth, cell proliferation and cell apoptosis in vivo. We found that DU145/NK4 cells expressed NK4 protein. In the in vitro study, autocrine NK4 attenuated the HGF-induced tumor cell proliferation, migration and invasion, and stimulated apoptosis. Furthermore, autocrine NK4 effectively inhibited the HGF-induced phosphorylation of c-Met, extracellular signal-regulated kinase-1 (ERK1). and protein kinase B 1/2 (Akt1/2). Histological examination revealed that autocrine NK4 inhibited proliferation and accelerated apoptosis of prostate cancer cells. These results show that genetic modification of DU145 cells with NK4 cDNA yields a significant effect on their proliferation, migration, invasion and apoptosis. Molecular targeting of HGF/c-Met by NK4 could be applied as a novel therapeutic approach to prostate cancer.
Yue
Dan
D
Cancer Research Institute, First Affiliated Hospital, China Medical University, Shenyang 110001, China.
Wang
Yong
Y
Ma
Ping
P
Li
Yin-Yan
YY
Chen
Hong
H
Wang
Ping
P
Ren
Chang-Shan
CS
D000230:Adenocarcinoma / Q000235:genetics* / Q000473:pathology; D000818:Animals; D017209:Apoptosis / Q000235:genetics; D019898:Autocrine Communication / Q000235:genetics; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000235:genetics; D049109:Cell Proliferation; D015972:Gene Expression Regulation, Neoplastic; D022761:Gene Transfer, Horizontal; D017228:Hepatocyte Growth Factor / Q000235:genetics*; D006801:Humans; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009361:Neoplasm Invasiveness / Q000235:genetics; D009368:Neoplasm Transplantation; D011471:Prostatic Neoplasms / Q000235:genetics* / Q000473:pathology; D014162:Transfection; D023041:Xenograft Model Antitumor Assays
C066855:HGF protein, human; D017228:Hepatocyte Growth Factor
Int J Cancer. 2005 Oct 20;117(1):160-5
15880501
Curr Gene Ther. 2002 Sep;2(3):323-39
12189719
Diabetologia. 2003 Jan;46(1):115-23
12637990
Cancer Res. 2000 Dec 1;60(23):6737-43
11118060
Int J Cancer. 2009 Sep 1;125(5):1004-15
19415747
Eur J Cancer. 2004 Sep;40(14):2135-42
15341989
Oncol Rep. 2003 Sep-Oct;10(5):1149-53
12883672
Adv Drug Deliv Rev. 2009 Jul 2;61(7-8):554-71
19394376
Breast Cancer Res Treat. 2008 Mar;108(1):43-55
17508279
Asian J Androl. 2009 Sep;11(5):541-7
19701218
J Egypt Natl Canc Inst. 2005 Jun;17(2):114-20
16508682
Prostate. 2004 Sep 1;60(4):317-24
15264243
Am J Pathol. 1995 Aug;147(2):386-96
7639332
Blood. 2007 Apr 1;109(7):3042-9
17179234
Prostate. 2009 Mar 1;69(4):346-51
19021204
Front Biosci. 2008 Jan 01;13:1943-51
17981681
Am J Pathol. 2004 Aug;165(2):533-40
15277227
Nat Rev Mol Cell Biol. 2003 Dec;4(12):915-25
14685170